Aaron Logan, MD, PhD
Professor
Medicine
School of Medicine

Dr. Logan and his laboratory are interested in methods for evaluating clonotypic diversity in the B and T lymphocyte repertoires in patients, particularly following hematopoietic cell transplantation when used to treat blood cancers, bone marrow failure disorders, and congenital immune deficiencies. Methods used in the laboratory currently include T cell receptor excision circle and kappa-deleting recombination circle (TREC/KREC) quantification, high-throughput sequencing of immunoglobulin and T cell receptor genes, and in vitro mixed lymphocyte reactions to identify T cells with specific reactivities. Efforts in the lab are focused on the application of immune repertoire profiling to quantify and track malignancy-, pathogen-, and autoantigen-targeted immune responses following allogeneic transplantation, as well as use of this platform to quantify measurable residual disease in lymphoid malignancies. In Dr. Logan’s lab, the Hematologic Malignancies Tissue Bank at UCSF has been built into a robust resource for samples isolated from patients with a wide diversity of blood cancers and following transplantation. These samples are made available in a deidentified manner to the UCSF and larger research community for cooperative discovery.

The phone number listed above is Dr. Logan's direct office number.

If you prefer to contact the outpatient clinic, please call 415-353-2421.

The clinic fax number is 415-353-2467.

• Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults.
  Journal of geriatric oncology 2023 Huang LW, Shi Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Boscardin WJ, Steinman MA, Olin RL
• Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
  Journal for immunotherapy of cancer 2023 Shah BD, Cassaday RD, Park JH, Houot R, Oluwole OO, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema …
• Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk Stratification.
  bioRxiv : the preprint server for biology 2023 Peretz CAC, Kennedy VE, Walia A, Delley CL, Koh A, Tran E, Clark IC, Hayford CE, D'Amato C, Xue Y, Fontanez KM, Roy R, Logan AC, Perl AE, Abate A, Olshen A, Smith CC
• Diagnosis and Management of Adult Malignancy-Associated Hemophagocytic Lymphohistiocytosis.
  Cancers 2023 Lee JC, Logan AC
• Demographics, Motivations, and Experiences of Participants in Transplantation or Cellular Therapy Fellowships.
  Transplantation and cellular therapy 2023 Banerjee R, Kelkar AH, Durani U, Anagnostou T, Nishitani M, Mallhi K, Majhail NS, Logan AC
• Lower leukemia burden maximizes the impact of blinatumomab therapy.
  Cancer 2023 Logan AC
• Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
  American journal of hematology 2023 Aldoss I, Shah BD, Park JH, Muffly L, Logan AC, Brown P, Stock W, Jabbour EJ
• Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
  Journal of hematology & oncology 2022 Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema…
• Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?
  Best practice & research. Clinical haematology 2022 Logan AC
• The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.
  Molecular cancer therapeutics 2022 Ferng TT, Terada D, Ando M, Tarver TC, Chaudhary F, Lin KC, Logan AC, Smith CC
• Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia.
  American journal of hematology 2022 Kennedy VE, Hui G, Azenkot T, Gaut D, Wieduwilt MJ, Oliai C, Jonas BA, Mittal V, Logan AC, Muffly LS, Mannis GN
• SOHO State of the Art Updates and Next Questions: Novel Transplant and Post-Transplant Options in Acute Lymphoblastic Leukemia.
  Clinical lymphoma, myeloma & leukemia 2022 Logan AC
• Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults.
  Transplantation and cellular therapy 2022 Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Huang CY, Olin RL
• Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
  British journal of haematology 2022 On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, Alegria W, Young R, Tan M, Kim C, Phun J, Patel N, Mannis G, Logan AC, Kennedy V, Goodman A, Taplitz RA, Young PA, Wen R, Saunders IM
• Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.
  Blood 2021 Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta R, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin J, Im A, …
• Anthracyclines in a patient with acute leukemia and severe cardiomyopathy requiring mechanical support: A case report.
  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2021 Banerjee R, Lo M, Klein L, Aras M, Logan AC
• Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.
  Blood cancer discovery 2021 Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye…
• KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
  Blood 2021 Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, Lin Y, Cassaday RD, Park JH, Abedi M, Castro JE, DeAngelo DJ, Malone AK, Mawad …
• Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
  European journal of haematology 2021 Ngai LL, Ma CY, Maguire O, Do AD, Robert A, Logan AC, Griffiths EA, Nemeth MJ, Green C, Pourmohamad T, van Kuijk BJ, Snel AN, Kwidama ZW, Venniker-Punt B, Cooper J, Manz MG, Gjertsen BT, Smit L, …
• KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
  Lancet (London, England) 2021 Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema…
• The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond.
  Current hematologic malignancy reports 2021 Banerjee R, Kelkar AH, Logan AC, Majhail NS, Pemmaraju N
• A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients.
  EClinicalMedicine 2021 Ljungman P, Bermudez A, Logan AC, Kharfan-Dabaja MA, Chevallier P, Martino R, Wulf G, Selleslag D, Kakihana K, Langston A, Lee DG, Solano C, Okamoto S, Smith LR, Boeckh M, Wingard JR, Cywin B, …
• Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation.
  Journal of geriatric oncology 2020 Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL
• Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia.
  Clinical advances in hematology & oncology : H&O 2020 Akabane H, Logan A
• Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation.
  Antimicrobial agents and chemotherapy 2020 Maertens J, Logan AC, Jang J, Long G, Tang JL, Hwang WYK, Koh LP, Chemaly R, Gerbitz A, Winkler J, Yeh SP, Hiemenz J, Christoph S, Lee DG, Wang PN, Holler E, Mielke S, Akard L, Yeo A, Ramachandra S, …
• Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019 Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Steinman MA, Huang CY, Olin RL
• Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019 Waller EK, Miklos D, Cutler C, Arora M, Jagasia MH, Pusic I, Flowers MED, Logan AC, Nakamura R, Chang S, Clow F, Lal ID, Styles L, Jaglowski S
• Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KML, Anderson K, Munster PN, Andreadis C
• Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
  Cancer discovery 2019 McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, …
• Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019.
  Journal of the National Comprehensive Cancer Network : JNCCN 2019 Brown PA, Wieduwilt M, Logan A, DeAngelo DJ, Wang ES, Fathi A, Cassaday RD, Litzow M, Advani A, Aoun P, Bhatnagar B, Boyer MW, Bryan T, Burke PW, Coccia PF, Coutre SE, Jain N, Kirby S, Liu A, Massaro …
• Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice.
  Blood 2019 Pang WW, Czechowicz A, Logan AC, Bhardwaj R, Poyser J, Park CY, Weissman IL, Shizuru JA
• Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019 Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL
• Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice.
  Blood 2019 Kwon HS, Logan AC, Chhabra A, Pang WW, Czechowicz A, Tate K, Le A, Poyser J, Hollis R, Kelly BV, Kohn DB, Weissman IL, Prohaska SS, Shizuru JA
• Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts.
  American journal of hematology 2018 Short NJ, Jabbour E, Albitar M, de Lima M, Gore L, Jorgensen J, Logan AC, Park J, Ravandi F, Shah B, Radich J, Kantarjian H
• Plasma Cell-Free DNA Next-Generation Sequencing to Diagnose and Monitor Infections in Allogeneic Hematopoietic Stem Cell Transplant Patients.
  Open forum infectious diseases 2018 Fung M, Zompi S, Seng H, Hollemon D, Parham A, Hong DK, Bercovici S, Dolan E, Lien K, Teraoka J, Logan AC, Chin-Hong P
• Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018 Fung M, Schwartz BS, Doernberg SB, Langelier C, Lo M, Graff L, Tan M, Logan AC, Chin-Hong P, Babik JM
• Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant.
  Case reports in hematology 2018 Rahmat LT, Nguyen A, Abdulhaq H, Prakash S, Logan AC, Mannis GN
• Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy.
  Drugs of today (Barcelona, Spain : 1998) 2018 Rahmat LT, Logan AC
• Hourigan CS and Logan AC. Measurable Residual Disease for AML, in: Emadi A and Karp JE (Eds). Acute Leukemia: an Illustrated Guide to Diagnosis and Treatment, Demos Medical, New York
  2018
• Logan AC. Sequence-specific MRD for ALL, in: Emadi A and Karp JE (Eds). Acute Leukemia: an Illustrated Guide to Diagnosis and Treatment. Demos Medical, New York
  2018
• Using Social Media at National Meetings in Hematology-Optimal Use, Tips, Strategies, and Limitations.
  Current hematologic malignancy reports 2017 Logan AC
• Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
  Blood 2017 Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S
• Obinutuzumab-induced serum sickness following salvage therapy for chronic lymphocytic leukemia.
  Clinical case reports 2017 Saba J, Logan AC
• The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters.
  Blood reviews 2017 Chan ST, Logan AC
• What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer.
  Annals of translational medicine 2016 Majure M, Logan AC
• Acute Liver Failure Secondary to Hemophagocytic Lymphohistiocytosis during Pregnancy.
  ACG case reports journal 2016 Giard JM, Decker KA, Lai JC, Gill RM, Logan AC, Fix OK
• Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.
  The Journal of clinical investigation 2016 Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B
• Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
  Blood 2016 Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB
• Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2016 Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS
• Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2016 Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC
• Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.
  Leukemia & lymphoma 2016 Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C
• Hematopoietic cell transplantation for chronic lymphocytic leukemia, in: Appelbaum FR, Forman SJ, Negrin RS, Antin JH (Eds). Thomas' Hematopoietic Cell Transplantation, 5th Ed, John Wiley & Sons, Ltd., Chichester, UK
  Hematopoietic cell transplantation for chronic lymphocytic leukemia, in: Appelbaum FR, Forman SJ, Negrin RS, Antin JH (Eds). Thomas' Hematopoietic Cell Transplantation, 5th Ed, John Wiley & Sons, Ltd., Chichester, UK. 2015 Logan AC, Miklos DB.
• Narrowband UV-B Phototherapy for Steroid-Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease.
  JAMA dermatology 2015 Sorenson E, McAndrew R, Patel V, Logan AC, Koo J, Levin E
• A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.
  Clinical lymphoma, myeloma & leukemia 2015 Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG
• ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2015 Logan AC, Wang Z, Alimoghaddam K, Wong RM, Lai T, Negrin RS, Grumet C, Logan BR, Zhang MJ, Spellman SR, Lee SJ, Miklos DB, Center for International Blood and Marrow Transplantation
• Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.
  Bone marrow transplantation 2014 Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, …
• Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.
  Proceedings of the National Academy of Sciences of the United States of America 2014 Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, Huang C, Swaminathan S, Sun H, Paietta E, Melnick AM, Koeffler P, Müschen M
• Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2014 Logan AC, Vashi N, Faham M, Carlton V, Kong K, Buño I, Zheng J, Moorhead M, Klinger M, Zhang B, Waqar A, Zehnder JL, Miklos DB
• Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.
  Leukemia 2013 Logan AC, Zhang B, Narasimhan B, Carlton V, Zheng J, Moorhead M, Krampf MR, Jones CD, Waqar AN, Faham M, Zehnder JL, Miklos DB
• Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options.
  Hematology (Amsterdam, Netherlands) 2012 Dunn T, Cho M, Medeiros B, Logan A, Ungewickell A, Liedtke M
• Cancer vaccines and T cell therapy.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012 Rezvani K, Brody JD, Kohrt HE, Logan AC, Advani R, Czerwinski DK, Weng WK, Negrin RS, Carlton V, Faham M, Levy R, Barrett J
• Accessory splenules in autoimmune hemolytic anemia.
  American journal of hematology 2012 Logan A, Berube C, Gotlib J
• The road to purified hematopoietic stem cell transplants is paved with antibodies.
  Current opinion in immunology 2012 Logan AC, Weissman IL, Shizuru JA
• Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia.
  Blood 2012 Gawad C, Pepin F, Carlton VE, Klinger M, Logan AC, Miklos DB, Faham M, Dahl G, Lacayo N
• Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer.
  Cancer investigation 2012 Riess JW, Logan AC, Krupitskaya Y, Padda S, Clément-Duchêne C, Ganjoo K, Colevas AD, Pedro-Salcedo MS, Kuo CJ, Wakelee HA
• Acute lymphoblastic leukemia, in Clinical Decision Support: Hospital Medicine, edited by Wiese J, Auerbach A, Glasheen J, Li J. Decision Support in Medicine, LLC. Wilmington, DE
  Acute lymphoblastic leukemia, in Clinical Decision Support: Hospital Medicine, edited by Wiese J, Auerbach A, Glasheen J, Li J. Decision Support in Medicine, LLC. Wilmington, DE. 2012 Malik UF, Dastaghyab N, Logan AC.
• High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.
  Proceedings of the National Academy of Sciences of the United States of America 2011 Logan AC, Gao H, Wang C, Sahaf B, Jones CD, Marshall EL, Buño I, Armstrong R, Fire AZ, Weinberg KI, Mindrinos M, Zehnder JL, Boyd SD, Xiao W, Davis RW, Miklos DB
• Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records.
  Annals of internal medicine 2011 Logan AC, Yank V, Stafford RS
• Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications.
  Annals of internal medicine 2011 Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS
• Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 May. Report No.: 10-EHC030-EF
  Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care. 2010 Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Stave CD, Zehnder JL, Olkin I, McDonald KM, Owens DK, Stafford RS.
• Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting.
  Hematology. American Society of Hematology. Education Program 2010 Logan AC, Goodnough LT
• Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma.
  Leukemia & lymphoma 2008 Kohrt H, Logan A, Temmins C, Witteles R, Liedtke M, Medeiros B
• Factors influencing the titer and infectivity of lentiviral vectors.
  Human gene therapy 2004 Logan AC, Nightingale SJ, Haas DL, Cho GJ, Pepper KA, Kohn DB
• Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration.
  Journal of virology 2004 Logan AC, Haas DL, Kafri T, Kohn DB
• The Moloney murine leukemia virus repressor binding site represses expression in murine and human hematopoietic stem cells.
  Journal of virology 2003 Haas DL, Lutzko C, Logan AC, Cho GJ, Skelton D, Jin Yu X, Pepper KA, Kohn DB
• Advances in lentiviral vector design for gene-modification of hematopoietic stem cells.
  Current opinion in biotechnology 2002 Logan AC, Lutzko C, Kohn DB